According to IMARC Group latest report titled “Telmisartan Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on telmisartan market outlook. The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global telmisartan market size reached US$ 3.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 3.7% during 2023-2028.
Request a Free Sample Report: https://www.imarcgroup.com/telmisartan-market/requestsample
Telmisartan is a pharmaceutical compound classified under the angiotensin II receptor blockers (ARBs) group, primarily prescribed for the management of hypertension and cardiovascular risk reduction in patients unable to take angiotensin-converting enzyme (ACE) inhibitors. It operates by blocking the action of certain natural substances that tighten the blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently. It is available in various dosages and formulations, including tablets and combination drugs that also contain diuretics for enhanced blood pressure control. Its advantages include a long half-life that supports once-daily dosing, minimal side effects, and additional benefits for patients with metabolic syndromes, making it a pivotal component in cardiovascular disease management strategies.
Market Trends:
The global market is majorly driven by the escalating prevalence of hypertension and cardiovascular diseases worldwide. Along with this, the rising awareness and screening initiatives for early hypertension detection contribute significantly to the increased demand for effective treatments, wherein Telmisartan plays a crucial role. Furthermore, the patent expiration of branded Telmisartan is leading to the emergence of generic versions, making it more accessible and affordable to a broader patient base. In addition, technological advancements in pharmaceuticals, alongside improved healthcare infrastructure and the expansion of healthcare coverage in emerging economies, are facilitating market expansion. Furthermore, ongoing research and development activities aiming at exploring novel therapeutic potentials and combination therapies involving Telmisartan are favoring the market. These factors, coupled with an aging global population and a growing focus on preventive healthcare measures, are propelling the market forward, reinforcing its importance in the global pharmaceutical landscape.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/telmisartan-market
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players operating in the market.
- The competitive landscape of the industry has also been examined along with the profiles of the key players operating in the market.
- Abbott Laboratories,
- Aurobindo Pharma USA,
- Boehringer Ingelheim International GmbH,
- Cipla Limited,
- Hikma Pharmaceuticals plc,
- Jubilant Cadista Pharmaceutical,
- Sanofi S.A.,
- Solco Healthcare (Prinston Pharmaceutical Inc.) and
- Torrent Pharmaceuticals Ltd.
Key Market Segmentation:
Our report has categorized the market based on region, indication and distribution channel.
Breakup by Indication:
- Hypertension
- Cardiovascular Risk Reduction
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, South Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
Comments